Brand-name drug
Zituvimet price, strengths & recalls
Brand of metformin / sitagliptin (generic)
Pharmacies pay $150.88 for 30 tablets of Zituvimet 1000 mg / 50 mg tablet this week, and from $150.29 to $302.34 across its 5 priced strengths and forms. The generic, metformin / sitagliptin, costs pharmacies from $75.28. Its official label last changed on January 6, 2026.
Brand- Fair cash price
- $184.01
- Strengths
- 5
- Makers
- 2
- Updated
- Nov 11
Zituvimet price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 500 mg / 50 mg (24 hr) extended-release tablet Brand | $5.01 | $150.29 / 30 tablets |
| 1000 mg / 100 mg (24 hr) extended-release tablet Brand | $10.08 | $302.34 / 30 tablets |
| 1000 mg / 50 mg (24 hr) extended-release tablet Brand | $5.02 | $150.72 / 30 tablets |
| 500 mg / 50 mg tablet Brand | $5.06 | $151.75 / 30 tablets |
| 1000 mg / 50 mg tablet Brand | $5.03 | $150.88 / 30 tablets |
The lowest cost per tablet is 500 mg / 50 mg (24 hr) extended-release tablet at $5.01. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Zituvimet vs generic metformin / sitagliptin
GenericMetformin / sitagliptin pricesSupply status: shortages & recalls
What people paid for Zituvimet
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use ZITUVIMET ®XR safely and effectively. See full prescribing information for ZITUVIMET ®XR.ZITUVIMET ®XR (sitagliptin and metformin hydrochloride) extended-release tablets, for oral useInitial U.S. Approval: 2007
BOXED WARNING
WARNING: LACTIC ACIDOSIS
Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1)].
Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment.
Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the full prescribing information [see Dosage and Administration (2.2), Contraindications (4), Warnings and Precautions (5.1), Drug Interactions (7), and Use in Specific Populations (8.6, 8.7)].
If metformin-associated lactic acidosis is suspected, immediately discontinue ZITUVIMET XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see Warnings and Precautions (5.1)].
WARNING: LACTIC ACIDOSIS
See full prescribing information for complete boxed warning.
Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL. (5.1)
Risk factors include renal impairment, concomitant use of certain drugs, age ≥65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high-risk groups are provided in the Full Prescribing Information. (5.1)
If lactic acidosis is suspected, discontinue ZITUVIMET XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. (5.1)
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA216778 · Zydus Lifesciences
- First approved
- July 18, 2024 (2 years ago)
- Latest approved change
- August 11, 2026
- Approved label
- PDF, Sep 11, 2026
- Generic makers
- 3 approved generic applications on the market
Zituvimet questions
How much does zituvimet cost without insurance?
Pharmacies pay about $150.88 for 30 tablets of zituvimet 1000 mg / 50 mg tablet ($5.03 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $184.01. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Zituvimet?
Yes: metformin / sitagliptin. Pharmacies pay from $75.28 for it. Compare metformin / sitagliptin prices.
Is zituvimet in shortage?
No shortage is reported for zituvimet right now. We check the national shortage list every day.
Has zituvimet been recalled?
No recalls are on record for zituvimet.
When did the zituvimet label last change?
The official label was last updated on January 6, 2026 (version 2). See what changed.
Talk about zituvimet
No comments yet. Questions, tips, what worked for you - start the conversation.